Paul Tudor Jones Alnylam Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 3,386 shares of ALNY stock, worth $798,926. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,386
Previous 60,393
94.39%
Holding current value
$798,926
Previous $14.7 Million
93.66%
% of portfolio
0.0%
Previous 0.08%
Shares
17 transactions
Others Institutions Holding ALNY
# of Institutions
644Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$3.9 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$2.98 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.25 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.24 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.17 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $29B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...